LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Search

Teva Pharmaceutical Industries Ltd.

Затворен

СекторЗдравеопазване

34.03 -0.38

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

34

Максимум

34.2

Ключови измерители

By Trading Economics

Приходи

-112M

369M

Продажби

-730M

4B

P/E

Средно за сектора

25.396

49.701

EPS

0.53

Марж на печалбата

9.269

Служители

31,173

EBITDA

245M

877M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+24.39% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

3.2B

40B

Предишно отваряне

34.41

Предишно затваряне

34.03

Настроения в новините

By Acuity

5%

95%

1 / 345 Класиране в Healthcare

Teva Pharmaceutical Industries Ltd. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.10.2025 г., 09:10 ч. UTC

Горещи акции

Stocks to Watch Thursday: HSBC, PepsiCo, MP Materials -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Teva Pharmaceutical Industries Ltd. Прогноза

Ценова цел

By TipRanks

24.39% нагоре

12-месечна прогноза

Среден 42.38 USD  24.39%

Висок 50 USD

Нисък 40 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Teva Pharmaceutical Industries Ltd. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

8

Купи

0

Задържане

0

Продай

Настроение

By Acuity

1 / 345 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
help-icon Live chat